Disease Markers

Disease Markers / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 2513026 | 9 pages | https://doi.org/10.1155/2019/2513026

Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Lung Cancer: A Meta-Analysis

Academic Editor: Timo Sorsa
Received29 Mar 2019
Accepted06 May 2019
Published01 Jul 2019


Background. The advanced lung cancer inflammation index (ALI) has been related to tumor survival in lung cancer (LC) patients. However, these findings regarding the prognostic relevance of ALI in LC were inconsistent. Our study is aimed at characterizing the prognostic significance of low pretreatment ALI in LC cases. Methods. Relevant published studies were systematically searched in several online databases. The combined hazard ratios (HRs) were applied to assess the correlation between ALI and overall/recurrence-free/progression-free survival (OS/PFS/RFS) in LC. Results. A total of 1587 LC patients from eight articles were recruited. Pooled results indicated that pretreatment ALI was significantly associated with prognosis in cases with LC. Compared to those with high-ALI, LC cases in the low-ALI group had a poorer OS (HR: 1.64, 95% CI: 1.34-1.93, ). Subgroup analyses further revealed the negative significant prognostic value of low ALI in LC. In addition, low ALI had obvious connection with inferior PFS/RFS (HR: 1.71, 95% CI: 1.35-2.07, ) in LC patients. Conclusions. Low ALI before treatments indicates poor prognosis in LC patients. Serum ALI may serve as a promising predictive tumor marker of survival in LC sufferers.

1. Introduction

Lung cancer (LC) is one of the most common and aggressive malignancies worldwide [1, 2]. It is estimated that there are 234,030 new diagnosed cases of lung and bronchus cancer and 154,050 died from it in 2018 alone in the United States [1]. And LC ranked first in all of the cancer-related deaths in China [3, 4]. In the pathological type, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) account for 85% and 15%, respectively. Despite the development and improvements of diagnosis and treatments in LC, the prognosis of LC remains unsatisfactory, with a low long-term survival rate. It is of importance to find a novel index with an accurate predictive value in LC cases therefrom.

The advanced lung cancer inflammation index (ALI), as a newly reported inflammation-based prognostic score, is based on body mass index (BMI), serum albumin (ALB), and neutrophil to lymphocyte ratio (NLR). It was calculated as [5]. The ALI was first evaluated as a powerful prognostic predictor in metastatic NSCLC [5], and subsequently, the usefulness of pretreatment ALI was evaluated as a prognostic marker in several types of malignancies, such as esophageal carcinoma and large B-cell lymphoma [6, 7]. In recent years, the role of ALI as a promising biomarker in LC attracted wide attention; more cohort studies worked on the relationship between pretreatment ALI and survival in LC patients [814]. However, the results in these published studies remain inconclusive [814], and no meta-analysis concerning the prognostic value of low ALI in LC patients is available so far. Therefore, in this study, we synthetically examined the correlation between pretreatment ALI and prognosis in LC via summarizing all currently available data. We hypothesized that low ALI could be a candidate predictor that is valuable for predicting survival and progression in LC.

2. Materials and Methods

2.1. Search Strategy and Study Selection

PubMed, Web of Science, and Embase were systematically searched for potential studies. The following keywords and terms were used: “advanced lung cancer inflammation index,” “ALI,” “lung cancer,” “lung tumor,” or “lung carcinoma.” The last update was Jan. 1, 2019, and no published language was restricted.

2.2. Inclusion and Exclusion Criteria

The inclusion criteria are as follows: (1)All recruited subjects were pathologically diagnosed with primary LC(2)The patients were divided into the low-ALI and high-ALI groups based on the pretreatment ALI levels(3)The HRs for the overall survival (OS), progression-free survival (PFS), or recurrence-free survival (RFS) were available

The exclusion criteria are as follows: reviews, abstracts, or posters or not involved in human lung cancer. And the latest study was included if there were overlapping data.

2.3. Data Extraction and Quality Assessment

Basic information of the included studies was extracted by two reviewers (Yi Zhang and Bo Chen), independently. The major features are listed in detail in Table 1. In addition, for the survival data, seven studies [5, 813] provided the HRs and 95% CIs in multivariate analysis for OS, and the HRs in multivariate analysis for PFS were reported in two studies [5, 14]. Only one study reported the HRs for RFS in univariate analysis [11]. If a study considered patients with high ALI as the reference, then, the data was converted to HR estimations considering cases with low ALI as a reference group to reflect the impact of low ALI on LC participants. Quality assessment was assessed using the method that was described in detail by Lin et al. [15].

Study (year)RegionPathological typeRecruitment periodTotal No. of casesGender (male/female)Age (years)End-pointCut-off valueSelection methodTherapyStageFollow-up (months)Multivariate analysis

Jafri et al. (2013) [5]USANSCLC2000-2011173116/57Median 57 (34-88)OS, PFS18ROC curveNo surgeryMetastatic<60Yes
He et al. (2015) [8]ChinaSCLC2006-2011365310/55Median 60 (22-82)OS19.5Cutoff finderNo surgeryMixed≥60Yes
Kim et al. (2016) [9]KoreaSCLC2010-2015186156/30Mean OS31.1Using chi-squared testNo surgeryMixed<60Yes
Bacha et al. (2017) [10]FranceNSCLC2010-20124141/0Mean 56.3OS23.2Median valueNo surgeryMetastatic<60Yes
Kobayashi et al. (2018) [11]JapanNSCLC2009-201416674/92NAOS, RFS22.2ROC curveWith surgeryNo metastatic≥60OS—yes; RFS—no
Ozyurek et al. (2018) [12]TurkeyNSCLC2006-201311294/18Mean OS18Median valueNo surgeryMetastatic≥60Yes
Tomita et al. (2018) [13]JapanNSCLC2008-2012343175/168NAOS37.66Cutoff finderWith surgeryNo metastatic≥60Yes
Shiroyama et al. (2018) [14]JapanNSCLC2015-2016201135/66Median 68 (27-87)PFS18Median valueNo surgeryMetastatic<60Yes

All studies included were retrospective study. NSCLC: non-small-cell lung cancer; SCLC: small-cell lung cancer; OS: overall survival; RFS: recurrence-free survival; PFS: progression-free survival; ROC: receiver operating characteristic curve; NA: not available.
2.4. Statistical Analysis

All statistical analyses were carried out using Stata/SE14.1 (Stata Corp LP, College Station, Texas, USA). The associations between low ALI and OS or PFS/RFS in lung cancer were expressed as the hazard ratios (HRs) with their corresponding 95% CIs. Heterogeneity across studies was evaluated by Cochran’s test and Higgins’ statistic. The fixed effect model was adopted for nonsignificant heterogeneity (, ). Publication bias was assessed by the visible plot and Begg’s test, and sensitivity analysis was performed for the measurement of the reliability of the combined results.

3. Results

The detailed selection procedure was listed (Figure 1). According to the abovementioned criteria, finally, a total of eight studies [5, 814] were considered to be eligible for this meta-analysis. There were altogether 1587 LC patients from eight retrospective studies with a mean sample size of 198.4. These studies were carried out in the USA (one study), China (one study), Korea (one study), France (one study), Japan (three studies), and Turkey (one study). Among them, seven studies reported OS, 2 studies covered PFS, and 1 study reported RFS. For the correlation between pretreatment ALI and OS, five studies worked on non-small-cell lung cancer (NSCLC), and two focused on small cell lung cancer (SCLC). The quality of the eight cohort studies was good with an average score of 7.25 (range 6-9; Figure 2, Table S1). The major characteristics of the recruited studies are summarized in Table 1.

3.1. ALI and OS

Seven cohort studies with a total of 1386 LC patients reported the HRs for the association between pretreatment ALI and OS. The pooled analysis found that pretreatment ALI was closely linked to the prognosis of OS, and the LC patients with low-ALI had a shorter survival time (HR: 1.64, 95% CI: 1.34-1.93, ) (Figure 3).

The prognostic values of low ALI in lung cancer were further displayed in subgroup analyses (Figures 4(a)4(d), Table 2). Notably, low ALI could act as an adverse prognostic factor of OS in NSCLC (HR: 1.64, 95% CI: 1.21-2.07, ) and SCLC (HR: 1.64, 95% CI: 1.24-2.05, ). And the clinical stages (metastatic vs. mixed vs. no metastatic), cut-off value (≥24.23 vs. <24.23), treatment methods (no surgery vs. with surgery), and the follow-up time (≥60 months vs. <60 months) all did not affect the significant predictive role of low-ALI in LC cases.

Subgroup factorNo. of cohort studiesCombined HR (95% CI) valueHeterogeneity

Pathological type
NSCLC51.64 (1.21-2.07)<0.00114.20.329
SCLC21.64 (1.24-2.05)<0.0010.00.898
Clinical stage
Metastatic31.51 (1.05-1.97)<0.0010.00.609
Nonmetastatic21.64 (1.24-2.05)<0.0010.00.898
Mixed22.40 (1.25-3.55)<0.00140.20.196
Cut-off value
<24.2351.57 (1.21-1.92)<0.0010.00.510
≥24.2321.80 (1.27-2.33)<0.0010.00.351
No surgery51.58 (1.28-1.89)<0.0010.00.881
With surgery22.40 (1.25-3.55)<0.00140.20.196
<60 m31.55 (1.17-1.93)<0.0010.00.597
≥60 m41.77 (1.30-2.24)<0.0014.70.369

3.2. ALI and PFS/RFS

Three cohort studies with 540 LC subjects investigated the correlation between pretreatment ALI and PFS/RFS. The combined results showed pretreatment low ALI indicated worse PFS/RFS in LC (HR: 1.71, 95% CI: 1.35-2.07, ), with no significant heterogeneity (, ) (Figure 5).

3.3. Publication Bias

For the OS, the shape of Begg’s funnel plot seems to be asymmetric () (Figure 6(a)), the estimated pooled result was still significant (, 95% CI: 1.402-1.952) after adjustment (Figure 6(b)) by the “trim-and-fill” method. For PFS/RFS, we did not conduct the publication bias assessment due to the small number of included studies.

3.4. Sensitivity Analysis

The sensitivity analysis indicated the results of our analyses were relatively stable in this meta-analysis (Figure 7).

4. Discussion

In the current meta-analysis, a total of eight studies from six countries were collected for prognostic analysis. And to our knowledge, this is the first meta-analysis that focused on this field. Finally, there were altogether 1587 cases suffering from NSCLC or SCLC in this study. The combined results revealed a significantly shorter OS in LC cases with low ALI compared to those with high ALI, and low pretreatment ALI was also correlated with worse PFS/RFS in LC patients. Hence, these results suggested that a low ALI score was a promising indicator displaying negative prognostic values in LC patients.

The ALI is related to cancer survival and could be a prognostic indicator in cancer. However, the specific mechanism for the predictive value of this scoring system is uncertain. According to the definition, a low ALI based on a decreased BMI, a lower Alb, and/or a high NLR indicates poor prognosis and high systemic inflammation. BMI levels might represent the nutritional status of patients. Some studies reported that BMI could be a predictive factor of OS benefit in some tumors [16, 17]. In addition, numerous studies have clarified a close association of inflammation and cancer [1821]; a series of inflammatory cytokines could reflect inflammatory response and participate in the tumor development and progression [21, 22]. Among them, serum albumin was demonstrated as an indicator in cancers; hypoalbuminemia was closely associated with poor prognosis in many tumors [2327]. In lung cancer, the low level of Alb was defined as a valuable index of poor survival rate and worse response [28, 29]. Furthermore, neutrophils and lymphocytes were recognized as two important factors in carcinogenesis [30, 31], and high NLR could be used as an independent negative marker of predicting prognosis in lung cancer [32, 33] and other malignancies, such as breast, colorectal, and esophageal cancers [3436].

Aside from the limited studies available, the present meta-analysis had several other limitations. Firstly, the included cohort data were of a retrospective design. Secondly, negative data were usually difficult to be published. Thirdly, there was a possibility of publication bias for OS. Fourthly, the prognostic role of low ALI for other secondary outcomes such as PFS/RFS in LC needed further validation. Finally, there are variations in several aspects, such as the ALI measurement methods and the cutoff values among these studies. Considering the limitations listed above, multicenter researches with a better-designed and larger sample are required to further validate the clinical value of ALI in LC.

In conclusion, from our analyses of eight cohort studies, we concluded that LC patients with a low ALI score have poor survival outcomes. LC patients with low-serum ALI had a shorter OS and worse PFS/RFS. Therefore, pretreatment ALI may act as a valuable candidate with a predictive power in LC.


ALI:Advanced lung cancer inflammation index
LC:Lung cancer
NSCLC:Non-small-cell lung cancer
SCLC:Small cell lung cancer
BMI:Body mass index
NLR:Neutrophil to lymphocyte ratio
HRs:Hazard ratios
OS:Overall survival
RFS:Recurrence-free survival
PFS:Progression-free survival
ROC:Receiver operating characteristic curve
NA:Not available.

Data Availability

All the original data were available in the included published articles.

Conflicts of Interest

The authors have stated that they have no conflicts of interest.

Supplementary Materials

Table S1: study quality of eight studies in the meta-analysis. (Supplementary Materials)


  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2018,” CA: A Cancer Journal for Clinicians, vol. 68, no. 1, pp. 7–30, 2018. View at: Publisher Site | Google Scholar
  2. L. A. Torre, R. L. Siegel, and A. Jemal, “Lung cancer statistics,” Advances in Experimental Medicine and Biology, vol. 893, pp. 1–19, 2016. View at: Publisher Site | Google Scholar
  3. X. Zhang, L. Wu, Y. Xu et al., “Trends in the incidence rate of lung cancer by histological type and gender in Sichuan, China, 1995–2015: A single‐center retrospective study,” Thoracic Cancer, vol. 9, no. 5, pp. 532–541, 2018. View at: Publisher Site | Google Scholar
  4. J. Kong, F. Xu, M. He, K. Chen, and B. Qian, “The incidence of lung cancer by histological type: a population-based study in Tianjin, China during 1981-2005,” Respirology, vol. 19, no. 8, pp. 1222–1228, 2014. View at: Publisher Site | Google Scholar
  5. S. H. Jafri, R. Shi, and G. Mills, “Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review,” BMC Cancer, vol. 13, no. 1, p. 158, 2013. View at: Publisher Site | Google Scholar
  6. J. F. Feng, Y. Huang, and Q. X. Chen, “A new inflammation index is useful for patients with esophageal squamous cell carcinoma,” OncoTargets and Therapy, vol. 7, pp. 1811–1815, 2014. View at: Publisher Site | Google Scholar
  7. Y. H. Park, H. G. Yi, M. H. Lee, C. S. Kim, and J. H. Lim, “Prognostic value of the pretreatment advanced lung cancer inflammation index (ALI) in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy,” Acta Haematologica, vol. 137, no. 2, pp. 76–85, 2017. View at: Publisher Site | Google Scholar
  8. X. He, T. Zhou, Y. Yang et al., “Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer,” Clinical Lung Cancer, vol. 16, no. 6, pp. e165–e171, 2015. View at: Publisher Site | Google Scholar
  9. E. Y. Kim, N. Kim, Y. S. Kim et al., “Prognostic significance of modified advanced lung cancer inflammation index (ALI) in patients with small cell lung cancer comparison with original ALI,” PLoS One, vol. 11, no. 10, article e0164056, 2016. View at: Publisher Site | Google Scholar
  10. S. Bacha, A. Sghaier, S. Habibech et al., “Advanced lung cancer inflammation index: a prognostic score in patients with metastatic non-small cell lung cancer,” La Tunisie Médicale, vol. 95, no. 11, pp. 976–981, 2017. View at: Google Scholar
  11. S. Kobayashi, Y. Karube, T. Inoue et al., “Advanced lung cancer inflammation index predicts outcomes of patients with pathological stage IA lung adenocarcinoma following surgical resection,” Annals of Thoracic and Cardiovascular Surgery, vol. 25, no. 2, pp. 87–94, 2019. View at: Publisher Site | Google Scholar
  12. B. A. Ozyurek, T. S. Ozdemirel, S. B. Ozden et al., “Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer?” The Clinical Respiratory Journal, vol. 12, no. 6, pp. 2013–2019, 2018. View at: Publisher Site | Google Scholar
  13. M. Tomita, T. Ayabe, and K. Nakamura, “The advanced lung cancer inflammation index is an independent prognostic factor after surgical resection in patients with non-small-cell lung cancer,” Interactive Cardiovascular and Thoracic Surgery, vol. 26, no. 2, pp. 288–292, 2018. View at: Publisher Site | Google Scholar
  14. T. Shiroyama, H. Suzuki, M. Tamiya et al., “Pretreatment advanced lung cancer inflammation index(ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer,” Cancer Medicine, vol. 7, no. 1, pp. 13–20, 2018. View at: Publisher Site | Google Scholar
  15. Y. Lin, Z. Liu, Y. Qiu et al., “Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: a systematic review and meta-analysis,” European Journal of Surgical Oncology, vol. 44, no. 10, pp. 1494–1503, 2018. View at: Publisher Site | Google Scholar
  16. A. G. Renehan, M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen, “Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies,” The Lancet, vol. 371, no. 9612, pp. 569–578, 2008. View at: Publisher Site | Google Scholar
  17. J. E. Olson, P. Yang, K. Schmitz, R. A. Vierkant, J. R. Cerhan, and T. A. Sellers, “Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women,” American Journal of Epidemiology, vol. 156, no. 7, pp. 606–615, 2002. View at: Publisher Site | Google Scholar
  18. B. J. Rollins, “Inflammatory chemokines in cancer growth and progression,” European Journal of Cancer, vol. 42, no. 6, pp. 760–767, 2006. View at: Publisher Site | Google Scholar
  19. K. Koizumi, S. Hojo, T. Akashi, K. Yasumoto, and I. Saiki, “Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response,” Cancer Science, vol. 98, no. 11, pp. 1652–1658, 2007. View at: Publisher Site | Google Scholar
  20. T. N. Hartmann, M. Burger, and J. A. Burger, “The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer,” Journal of Biological Regulators and Homeostatic Agents, vol. 18, no. 2, pp. 126–130, 2004. View at: Google Scholar
  21. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at: Publisher Site | Google Scholar
  22. M. Sabzevary-Ghahfarokhi, H. Shirzad, M. Rafieian-Kopaei, M. Ghatreh-Samani, and M. Shohan, “The role of inflammatory cytokines in creating T cell exhaustion in cancer,” Cancer Biotherapy & Radiopharmaceuticals, vol. 33, no. 7, pp. 267–273, 2018. View at: Publisher Site | Google Scholar
  23. X. Ouyang, Y. Dang, F. Zhang, and Q. Huang, “Low serum albumin correlates with poor survival in gastric cancer patients,” Clinical Laboratory, vol. 64, 2018. View at: Publisher Site | Google Scholar
  24. J. Huang, Y. Wang, Y. Yuan et al., “Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy,” Oncotarget, vol. 8, no. 22, pp. 36772–36779, 2017. View at: Publisher Site | Google Scholar
  25. S. González-Trejo, J. F. Carrillo, D. D. Carmona-Herrera et al., “Baseline serum albumin and other common clinical markers are prognostic factors in colorectal carcinoma: a retrospective cohort study,” Medicine, vol. 96, no. 15, article e6610, 2017. View at: Publisher Site | Google Scholar
  26. Y. X. Xu, Y. B. Wang, Y. L. Tan, C. Xi, and X. Z. Xu, “Prognostic value of pretreatment albumin to bilirubin ratio in patients with hepatocellular cancer: a meta-analysis,” Medicine, vol. 98, no. 2, article e14027, 2019. View at: Publisher Site | Google Scholar
  27. H. Sun, P. Hu, H. Shen et al., “Albumin and neutrophil combined prognostic grade as a new prognostic factor in non-small cell lung cancer: results from a large consecutive cohort,” PLoS One, vol. 10, no. 12, article e0144663, 2015. View at: Publisher Site | Google Scholar
  28. Y. Jin, L. Zhao, and F. Peng, “Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer,” Clinics, vol. 68, no. 5, pp. 686–693, 2013. View at: Publisher Site | Google Scholar
  29. E. Espinosa, J. Feliu, P. Zamora et al., “Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer,” Lung Cancer, vol. 12, no. 1-2, pp. 67–76, 1995. View at: Publisher Site | Google Scholar
  30. J. Á. Nicolás-Ávila, J. M. Adrover, and A. Hidalgo, “Neutrophils in homeostasis, immunity, and cancer,” Immunity, vol. 46, no. 1, pp. 15–28, 2017. View at: Publisher Site | Google Scholar
  31. B. Farhood, M. Najafi, and K. Mortezaee, “CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review,” Journal of Cellular Physiology, vol. 234, no. 6, pp. 8509–8521, 2018. View at: Publisher Site | Google Scholar
  32. S. Diem, S. Schmid, M. Krapf et al., “Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab,” Lung Cancer, vol. 111, pp. 176–181, 2017. View at: Publisher Site | Google Scholar
  33. S. J. Bagley, S. Kothari, C. Aggarwal et al., “Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer,” Lung Cancer, vol. 106, pp. 1–7, 2017. View at: Publisher Site | Google Scholar
  34. D. A. Patel, J. Xi, J. Luo et al., “Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer,” Breast Cancer Research and Treatment, vol. 174, no. 2, pp. 443–452, 2019. View at: Publisher Site | Google Scholar
  35. N. Dimitriou, E. Felekouras, I. Karavokyros, A. Alexandrou, E. Pikoulis, and J. Griniatsos, “Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients,” BMC Cancer, vol. 18, no. 1, p. 1202, 2018. View at: Publisher Site | Google Scholar
  36. Y. Sun and L. Zhang, “The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis,” Cancer Management and Research, vol. 10, pp. 6167–6179, 2018. View at: Publisher Site | Google Scholar

Copyright © 2019 Yi Zhang and Bo Chen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

513 Views | 259 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.